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hazard of death for treatment C. If the 
ratio of hazards r(t)=λ
e
(t)/λ
c
(t) does not 
depend on time t then the proportional 
hazards assumption holds. Denoting 
this ratio by HR we can interpret HR 
= 0.75 (without reference to time) as 
“patients on treatment E have a 25% 
reduced risk of death relative to treat-
ment C.” If we switch the interpretation 
to be in terms of C relative to E then this 
is λ
c
(t)/λ
e
(t)=1/HR, which means that 
the hazard for C is (1/0.75) or 133% 
the hazard of E. Note that [λ
c
(t)–λ
e
(t)]/
λ
e
(t)=1/HR − 1, where λ
c
(t)–λ
e
(t) repre-
sents how much treatment C increases 
the hazard of death compared with E. 
Then 1/HR − 1 = 33% is the percentage 
increase in the hazard of death for treat-
ment C relative to treatment E.
Because survival probabilities 
(OS curves) are an explicit mathematical 
expression of the hazard function, that 
“treatment E reduces the risk (hazard) 
of death” already directly translates into 
prolonged OS for E relative to C. As we 
design trials to assess whether an experi-
mental regimen prolongs OS relative to a 
control, the interpretation given by 1 − HR 
(E versus C) is what is needed.
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conduct a large prospective study (cur-
rently ongoing in our institution).
Finally, we once again thank Dr. 
Ismaili for his thoughtful comments and 
we are grateful to get the opportunity to 
clarify some points from our work. 
Ibrahim Elghissassi, MD 
Hassan Errihani, MD
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appropriate and is standard throughout 
the statistical and medical literature. The 
interpretation provided by (2), however, 
is not sound and can cause considerable 
miscommunication of study results. 
Statement (2) suggests that treatment 
E extends the survival times of patients 
after treatment E by 33% compared with 
the survival times of patients after treat-
ment C. For example, 1-year OS under 
treatment C is extended to 1.33 years 
under treatment E, 2-year OS extended 
to 2.66 years, and so on. The degree of 
improvement in OS times or probabili-
ties cannot by itself be summarized by a 
single value as survival differences will 
vary across time. Although the HR is 
generally considered the most important 
comprehensive summary of survival 
comparisons, its interpretation should 
not be taken out of context.
The authors’ interpretation 
assumes that survival times follow an 
exponential distribution. In this case, 
when both treatment groups follow expo-
nential distributions, then the ratio of 
medians, m
e
/m
c
 (say), is equal to 1/HR. 
The exponential model, however, should 
not be the basis for general interpreta-
tion. For example, suppose that treat-
ment C survival times follow a Weibull 
model with shape parameter ν and scale 
parameter θ (cf. ref.2), and that the hazard 
function for treatment E is equal to three-
fourths the hazard function for treatment 
C. We note that the exponential model is 
a special case of the Weibull model with 
shape parameter ν=1. Then HR=0.75 
and the ratio of medians is equal to 1/
HR=1.33 if and only if ν=1. However, 
if ν=0.25, for example, then the ratio of 
medians is equal to 3.16, and if ν=4, then 
the ratio is 1.07. These examples illus-
trate the pitfalls of interpreting 1/HR as 
the “increase in survival time.”
Here we clarify that for HR=0.75, 
1 − HR = 0.25 means that “treatment E 
reduces the risk of death by 25% rela-
tive to treatment C,” whereas 1/HR − 1 = 
0.33 means that “treatment C increases 
the risk of death by 33% relative to 
treatment E.” In other words, convert-
ing the interpretation from 1 − HR to 
1/HR − 1 simply changes the reference 
group; from E versus C to C versus E. 
This can be seen from the definition 
of the HR. Let λ
e
 denote the hazard of 
death for treatment E, and λ
c
 denote the 
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In their article, Barraclough et 
al.1 provide important insights into 
the interpretation of hazard ratio 
(HR) estimates from Cox models and 
Kaplan–Meier curves from clinical tri-
als. Unfortunately, the authors provide 
a particular interpretation of the HR, 
which can distort both statistical and 
clinical interpretations. Specifically, 
the authors interpret (see ref.,1 p. 981, 
Box 2) a 0.75 HR for overall survival 
(OS), comparing treatment E (experi-
mental) versus C (control), as either (1) 
a 25% lower risk of death (via 100 × 
(1 − HR)%, denoted 1 − HR), or (2) a 
33% increase in the survival time (via 
100 × (1/HR − 1)%, denoted 1/HR − 1). 
The interpretation provided by (1) is 
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We appreciate the opportunity 
to reply to the letter by Leon et al. 
in response to our article on Hazard 
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Ratios as a part of Biostatistics 
Primer: What a Clinician Ought to 
Know which was published more than 
2 years ago. The statements made in 
the article are correct and valid under 
the assumptions and caveats that 
were clearly stated. The authors of 
the letter have simply expanded the 
role of these assumptions and caveats 
clearly stated in the article in statisti-
cal terms.
As acknowledged by the authors 
of the letter to the editor, our interpreta-
tion of the hazard ratio in terms of “% 
increase in survival time” is correct for 
the median (and indeed for any quantile 
or simply put, any point on the curve) 
under the assumption that the survival 
times follow an exponential distribu-
tion. Our assumption that the survival 
data follow an exponential distribution 
is clearly stated in Box 2 and in the 
adjacent sentence to that in which we 
discuss “% increase in survival time.” 
The authors of the letter instead dispute 
that this can be used as the basis for 
general interpretation.
The hazard ratio is clearly 
defined and discussed in the major-
ity of the articles in terms of the risk 
of death, but because the scale of “% 
improvement in survival” is attractive 
to many clinicians and sometimes used 
in communications targeted to them, 
we wanted to also relate this to the haz-
ard ratio in simple terms. The assump-
tion of exponential distributions is 
convenient when considering survival 
data in general because of its simplic-
ity and hence is popular in teaching 
concepts. In particular in this case, as 
the authors of the letter note, without 
such an assumption, “the degree of 
improvement in overall survival times 
or probabilities cannot themselves be 
summarized by a single value as sur-
vival differences will vary across time.” 
Consequently, we relied on the assump-
tion of exponentially distributed data to 
make the link between the hazard ratio 
and the “% improvement in survival,” 
but were careful to state in the article 
both this assumption and the important 
caveats that “any such improvement or 
reduction in survival should be inter-
preted in the context of the Kaplan-
Meier curve as a whole” (where the 
actual observed % improvement can be 
read off the graph) and used the terms 
“on average” and “approximately” 
for the interpretation in terms of “% 
improvement in survival.” We think 
that these caveats are sufficient to pre-
vent overinterpretation.
We believe that in our article the 
approach taken to describe a statistical 
concept in simple terms in a way that 
is relevant to the readership (directed 
mainly to the clinicians), while includ-
ing appropriate caveats and assump-
tions, was consistent with the goals of 
the educational series. 
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